Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.51 |
| ▸ | JAK2 | O60674 | 7/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448615 | 1.00 | RIPK1 (0.51) | RIPK1JAK2NTRK1PIK3CDCYP1A2 | |
| SCHEMBL433245 | 1.00 | RIPK1 (0.51) | RIPK1JAK2NTRK1PIK3CDCYP1A2 | |
| SCHEMBL448616 | 1.00 | RIPK1 (0.51) | RIPK1JAK2NTRK1PIK3CDCYP1A2 | |
| SCHEMBL29429632 | 1.00 | RIPK1 (0.51) | RIPK1JAK2NTRK1PIK3CDCYP1A2 | |
| SCHEMBL461286 | 0.88 | RIPK1 (0.49) | RIPK1JAK2NTRK1PIK3CDPDE5A | |
| SCHEMBL10280117 | 0.88 | RIPK1 (0.51) | RIPK1JAK2NTRK1PDE5ANR1H2 | |
| SCHEMBL29744513 | 0.88 | RIPK1 (0.51) | RIPK1JAK2NTRK1PDE5ANR1H2 | |
| SCHEMBL430761 | 0.88 | RIPK1 (0.51) | RIPK1JAK2NTRK1PDE5ANR1H2 | |
| SCHEMBL433225 | 0.88 | RIPK1 (0.51) | RIPK1JAK2NTRK1PDE5ANR1H2 | |
| SCHEMBL445277 | 0.88 | RIPK1 (0.51) | RIPK1JAK2NTRK1PDE5ANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103492384-B | As compound and the composition of TRK inhibitor | NOVARTIS AG (CH) | 2016-05-11 | — | — | CN | disclosed |
| EP-2678338-B1 | PYRAZOLO[1,5-A]PYRIDINES AS TRK INHIBITORS | NOVARTIS AG (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2678338-B1 | PYRAZOLO[1,5-A]PYRIDINES AS TRK INHIBITORS | NOVARTIS AG (CH) | 2015-09-09 | — | — | EP | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| EP-2678338-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2014-01-01 | — | — | EP | disclosed |
| CN-103492384-A | Compounds and compositions as trk inhibitors | IRM LLC | 2014-01-01 | — | — | CN | disclosed |
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-12-12 | — | — | US | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012034095-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | CNKSR1, BMP2K, RAF1 | RIPK1 239/4885JAK2 598/4885NTRK1 92/4885 |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | RIPK1 168/4885JAK2 615/4885NTRK1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.